Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR17 | Q13304 | 2/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 10/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22989758 | 0.86 | GPR17 (0.47) | GPR17FFAR4FFAR1POLBNPSR1 | |
| SCHEMBL4717045 | 0.81 | FFAR1 (0.49) | FFAR4FFAR1POLBNPSR1KEAP1 | |
| SCHEMBL25246670 | 0.81 | AKR1B1 (0.44) | GPR17 | |
| SCHEMBL31674134 | 0.80 | MEP1B (0.53) | GPR17FFAR4FFAR1POLBNPSR1 | |
| SCHEMBL28123344 | 0.79 | POLB (0.51) | FFAR4FFAR1POLBNPSR1KEAP1 | |
| SCHEMBL23655932 | 0.78 | NPSR1 (0.55) | FFAR4FFAR1POLBNPSR1 | |
| SCHEMBL1838229 | 0.77 | GPR17 (0.43) | GPR17FFAR4FFAR1POLB | |
| SCHEMBL22253648 | 0.77 | FFAR4 (0.52) | GPR17FFAR4FFAR1 | |
| SCHEMBL5152941 | 0.77 | NPSR1 (0.44) | GPR17FFAR4FFAR1POLBNPSR1 | |
| SCHEMBL19522398 | 0.76 | GPR17 (0.55) | GPR17FFAR4FFAR1KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404265-B2 | Substituted pyridine derivatives as SARM1 inhibitors | NURA BIO, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-11970481-B1 | Substituted pyridine derivatives as SARM1 inhibitors | NURA BIO, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| US-20240116901-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | NURA BIO, INC. | 2024-04-11 | — | — | US | disclosed |
| US-20230339913-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | NURA BIO, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230339913-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | NURA BIO, INC. | 2023-10-26 | — | — | US | disclosed |
| EP-4192828-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | Nura Bio, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404265-B2 | Substituted pyridine derivatives as SARM1 inhibitors | SARM1, SARNP, ADRM1 | GPR17 4583/4885FFAR4 4580/4885FFAR1 4246/4885 |
| US-11970481-B1 | Substituted pyridine derivatives as SARM1 inhibitors | SARM1, SARNP, ADRM1 | GPR17 4583/4885FFAR4 4580/4885FFAR1 4246/4885 |
| US-20230339913-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | SARM1, SARNP, ADRM1 | GPR17 4583/4885FFAR4 4580/4885FFAR1 4246/4885 |
| US-20240116901-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | SARM1, SARNP, ADRM1 | GPR17 4583/4885FFAR4 4580/4885FFAR1 4246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.